AUSTIN, Texas, Aug. 5 -- The University of Texas at Austin issued the following news release:
Pancreatic tumors can resist immunotherapy by recruiting nearby immune cells to help protect them, according to researchers at The University of Texas at Austin. The findings, published in Nature Communications, also point to a potential new strategy for overcoming resistance and improving cellular therapies.
Pancreatic ductal adenocarcinoma, the most common type of pancreatic cancer, is projected to become the second leading cause of cancer death in the United States by 2030. CAR T-cell therapy, which re-engineers a patient's own T cells to hunt tumors, has transformed treatment for several blood cancers but has repeatedly stalled against solid ...